Skip to main content

Table 3 Percentage of antifungals MICs for Aspergillus species with ECVs

From: Hospital distribution, seasonality, time trends and antifungal susceptibility profiles of all Aspergillus species isolated from clinical samples from 2015 to 2022 in a tertiary care hospital

Species

Antifungal agent

% of isolates with MIC (µg/mL) of

 ≤ 0.008

0.0156

0.0312

0.06

0.12

0.25

0.5

1

2

4

 ≥ 8

ECV (µg/mL)

A. fumigatus

AMB

0.0

0.0

0.4

0.0

1.6

0.8

5.8

16.5

63.7

9.3

1.6

2

VRC

0.0

0.0

0.4

1.6

13.5

51.9

28.4

3.6

0.6

0.0

0.0

1

PSC

7.1

29.7

41.6

11.3

5.3

4.0

0.8

0.2

0.0

0.0

0.0

0.5

ITR

0.0

14.4

30.9

32.1

13.5

6.3

2.1

0.5

0.0

0.2

0.0

1

A. niger

AMB

0.0

0.0

0.0

0.0

0.8

5.2

3.2

15.7

53.2

20.6

1.2

2

VRC

0.0

0.0

0.8

3.6

11.2

20.3

36.7

25.9

0.4

0.0

0.8

2

PSC

4.6

11.2

14.1

34.0

22.0

6.2

5.8

2.1

0.0

0.0

0.0

2

ITR

0.0

10.7

9.2

13.6

30.6

20.4

9.2

5.3

1.0

0.0

0.0

4

A. flavus

AMB

0.0

0.0

0.0

0.0

0.5

0.5

3.5

12.1

25.8

54.5

3.0

4

VRC

0.0

0.0

0.5

1.5

7.5

17.6

39.7

30.7

2.0

0.5

0.0

2

PSC

3.1

5.6

10.8

40.5

22.1

12.8

3.1

2.1

0.0

0.0

0.0

0.5

ITR

0.0

9.9

15.2

35.1

21.1

14.6

3.5

0.0

0.0

0.6

0.0

1

A. terreus

AMB

0.0

0.0

0.0

0.0

0.0

0.9

0.9

4.3

27.4

65.0

1.7

4

VRC

0.0

0.0

0.8

1.7

16.0

33.61

41.2

6.7

0.0

0.0

0.0

2

PSC

6.0

38.5

31.6

12.8

6.8

4.3

0.0

0.0

0.0

0.0

0.0

1

ITR

0.0

41.0

32.4

15.2

8.6

2.9

0.0

0.0

0.0

0.0

0.0

2

  1. MIC values above the corresponding ECV are in bold
  2. AMB amphotericin B, VRC voriconazole, PSC posaconazole, ITR itraconazole